The European Medicines Agency recently launched a public consultation on draft Questions and answers on implementation of risk based prevention of cross contamination in production and ‘Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities’ (EMA/CHMP/CVMP/SWP/169430/2012). EIPG has reviewed the document and, following feedback from its members, has submitted its comments to the EMA.
-
-
News from EIPG
- Annex 1 – a focus on its main issues (Webinar)
- How a pandemic has affected the pharma industry (Webinar)
- EIPG publishes updated version of Code of Practice for Qualified Persons
- Consultation on Annex 21: Importation of medicinal products, of the EudraLex Volume 4 (Webinar)
- The role of the body clock in drug development, efficacy and toxicity (Webinar)
- Medicines shortages: root causes and potential solutions
- GMP documentation management: requirements and best practices (Webinar)
